Expiring Drug Patents Cheat Sheet
We analyse the patents covering drugs in 134 countries and quickly give you the likely loss-of-exclusivity/generic entry date

Generic name: alcohol
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: June 21, 2025
Generic Entry Controlled by: United States FDA Regulatory Exclusivity

ABLYSINOL is a drug marketed by Bpi Labs.

The generic ingredient in ABLYSINOL is alcohol. There are forty-one drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the alcohol profile page.

Generic name: bremelanotide acetate
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: June 28, 2025
Generic Entry Controlled by: United States Patent Patent 6,794,489

VYLEESI (AUTOINJECTOR) is a drug marketed by Cosette. There are five patents protecting this drug.

This drug has eighty-one patent family members in twenty-six countries.

The generic ingredient in VYLEESI (AUTOINJECTOR) is bremelanotide acetate. One supplier is listed for this generic product. Additional details are available on the bremelanotide acetate profile page.

Generic name: naltrexone hydrochloride; oxycodone hydrochloride
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: July 03, 2025
Generic Entry Controlled by: United States Patent Patent 8,685,443

TROXYCA ER is a drug marketed by Pfizer. There are two patents protecting this drug.

This drug has sixteen patent family members in twelve countries.

The generic ingredient in TROXYCA ER is naltrexone hydrochloride; oxycodone hydrochloride. There are nineteen drug master file entries for this API. Additional details are available on the naltrexone hydrochloride; oxycodone hydrochloride profile page.

Generic name: tafenoquine succinate
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: July 20, 2025
Generic Entry Controlled by: United States FDA Regulatory Exclusivity

KRINTAFEL is a drug marketed by Glaxosmithkline.

This drug has sixteen patent family members in twelve countries.

See drug price trends for KRINTAFEL.

The generic ingredient in KRINTAFEL is tafenoquine succinate. Two suppliers are listed for this generic product. Additional details are available on the tafenoquine succinate profile page.

Generic name: testosterone undecanoate
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: July 27, 2025
Generic Entry Controlled by: United States FDA Regulatory Exclusivity

KYZATREX is a drug marketed by Marius Pharms Llc. There are four patents protecting this drug. One tentatively approved generic is ready to enter the market.

This drug has twenty patent family members in eleven countries.

See drug price trends for KYZATREX.

The generic ingredient in KYZATREX is testosterone undecanoate. There are sixty-nine drug master file entries for this API. Six suppliers are listed for this generic product. Additional details are available on the testosterone undecanoate profile page.

Generic name: fish oil triglycerides
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: July 27, 2025
Generic Entry Controlled by: United States FDA Regulatory Exclusivity

OMEGAVEN is a drug marketed by Fresenius Kabi Usa. There are two patents protecting this drug.

This drug has five patent family members in four countries. There has been litigation on patents covering OMEGAVEN

See drug price trends for OMEGAVEN.

The generic ingredient in OMEGAVEN is fish oil triglycerides. There are six drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the fish oil triglycerides profile page.

Generic name: iobenguane i-131
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: July 30, 2025
Generic Entry Controlled by: United States FDA Regulatory Exclusivity

AZEDRA is a drug marketed by Progenics Pharms Inc.

This drug has five patent family members in four countries.

See drug price trends for AZEDRA.

The generic ingredient in AZEDRA is iobenguane i-131. Additional details are available on the iobenguane i-131 profile page.

Generic name: migalastat hydrochloride
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: August 10, 2025
Generic Entry Controlled by: United States FDA Regulatory Exclusivity

GALAFOLD is a drug marketed by Amicus Therap Us. There are sixty-three patents protecting this drug.

This drug has two hundred and fifty-four patent family members in thirty countries. There has been litigation on patents covering GALAFOLD

The generic ingredient in GALAFOLD is migalastat hydrochloride. One supplier is listed for this generic product. Additional details are available on the migalastat hydrochloride profile page.

Generic name: estradiol acetate
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: October 02, 2025
Generic Entry Controlled by: United States Patent Patent 7,572,779

FEMTRACE is a drug marketed by Apil. There is one patent protecting this drug.

This drug has eleven patent family members in ten countries.

The generic ingredient in FEMTRACE is estradiol acetate. There are seventy-five drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the estradiol acetate profile page.

Generic name: rilpivirine hydrochloride
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: October 21, 2025
Generic Entry Controlled by: United States Patent Patent 7,125,879

EDURANT is a drug marketed by Janssen Prods. There are three patents protecting this drug.

This drug has one hundred and ninety-nine patent family members in forty-two countries. There has been litigation on patents covering EDURANT

See drug price trends for EDURANT.

The generic ingredient in EDURANT is rilpivirine hydrochloride. There are seven drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the rilpivirine hydrochloride profile page.

Generic name: gallium ga-68 psma-11
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: December 01, 2025
Generic Entry Controlled by: United States FDA Regulatory Exclusivity

GALLIUM GA 68 PSMA-11 is a drug marketed by

This drug has one hundred and ninety-nine patent family members in forty-two countries.

The generic ingredient in GALLIUM GA 68 PSMA-11 is gallium ga-68 psma-11. There are sixteen drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the gallium ga-68 psma-11 profile page.

Generic name: nepafenac
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: December 02, 2025
Generic Entry Controlled by: United States Patent Patent 8,071,648

NEVANAC is a drug marketed by Harrow Eye. There are three patents protecting this drug.

This drug has twenty-seven patent family members in twenty-three countries.

See drug price trends for NEVANAC.

The generic ingredient in NEVANAC is nepafenac. There are eight drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the nepafenac profile page.

Generic name: abaloparatide
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: December 19, 2025
Generic Entry Controlled by: United States FDA Regulatory Exclusivity

TYMLOS is a drug marketed by Radius. There are nine patents protecting this drug.

This drug has fifty-four patent family members in twenty-eight countries. There has been litigation on patents covering TYMLOS

See drug price trends for TYMLOS.

The generic ingredient in TYMLOS is abaloparatide. One supplier is listed for this generic product. Additional details are available on the abaloparatide profile page.

Generic name: tapentadol hydrochloride
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: December 27, 2025
Generic Entry Controlled by: United States Patent Patent 7,994,364

NUCYNTA ER is a drug marketed by Collegium Pharm Inc. There are three patents protecting this drug and one Paragraph IV challenge. Three tentatively approved generics are ready to enter the market.

This drug has ninety-six patent family members in twenty-seven countries. There has been litigation on patents covering NUCYNTA ER

See drug price trends for NUCYNTA ER.

The generic ingredient in NUCYNTA ER is tapentadol hydrochloride. There are five drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the tapentadol hydrochloride profile page.

Generic name: albuterol sulfate; budesonide
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: January 10, 2026
Generic Entry Controlled by: United States FDA Regulatory Exclusivity

AIRSUPRA is a drug marketed by Astrazeneca. There is one patent protecting this drug.

This drug has one hundred and eighty-four patent family members in thirty-one countries.

See drug price trends for AIRSUPRA.

The generic ingredient in AIRSUPRA is albuterol sulfate; budesonide. There are thirty-eight drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the albuterol sulfate; budesonide profile page.

Generic name: chlorhexidine gluconate; isopropyl alcohol
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: January 20, 2026
Generic Entry Controlled by: United States FDA Regulatory Exclusivity

SOLUPREP is a drug marketed by 3m Health Care.

This drug has one hundred and eighty-four patent family members in thirty-one countries.

The generic ingredient in SOLUPREP is chlorhexidine gluconate; isopropyl alcohol. There are fifty-eight drug master file entries for this API. Four suppliers are listed for this generic product. Additional details are available on the chlorhexidine gluconate; isopropyl alcohol profile page.

Generic name: voclosporin
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: January 22, 2026
Generic Entry Controlled by: United States FDA Regulatory Exclusivity

LUPKYNIS is a drug marketed by Aurinia. There are three patents protecting this drug.

This drug has one hundred and ninety-six patent family members in forty countries. There has been litigation on patents covering LUPKYNIS

See drug price trends for LUPKYNIS.

The generic ingredient in LUPKYNIS is voclosporin. There is one drug master file entry for this API. One supplier is listed for this generic product. Additional details are available on the voclosporin profile page.

Generic name: methotrexate
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: January 24, 2026
Generic Entry Controlled by: United States Patent Patent 9,629,959

OTREXUP is a drug marketed by Otter Pharms. There are fourteen patents protecting this drug.

This drug has thirty-nine patent family members in fourteen countries. There has been litigation on patents covering OTREXUP

See drug price trends for OTREXUP.

The generic ingredient in OTREXUP is methotrexate. There are twenty drug master file entries for this API. Four suppliers are listed for this generic product. Additional details are available on the methotrexate profile page.

Generic name: estradiol; norethindrone acetate; relugolix
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: January 28, 2026
Generic Entry Controlled by: United States Patent Patent 7,300,935

MYFEMBREE is a drug marketed by Sumitomo Pharma. There are six patents protecting this drug.

This drug has one hundred and forty-five patent family members in thirty-five countries.

See drug price trends for MYFEMBREE.

The generic ingredient in MYFEMBREE is estradiol; norethindrone acetate; relugolix. There are seventy-five drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the estradiol; norethindrone acetate; relugolix profile page.

Generic name: triclabendazole
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: February 13, 2026
Generic Entry Controlled by: United States FDA Regulatory Exclusivity

EGATEN is a drug marketed by Novartis.

This drug has one hundred and forty-five patent family members in thirty-five countries.

The generic ingredient in EGATEN is triclabendazole. There is one drug master file entry for this API. One supplier is listed for this generic product. Additional details are available on the triclabendazole profile page.

Generic name: liraglutide recombinant
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: February 13, 2026
Generic Entry Controlled by: United States Patent Patent 8,114,833

SAXENDA is a drug marketed by Novo. There are two patents protecting this drug.

This drug has sixty-three patent family members in twenty-seven countries. There has been litigation on patents covering SAXENDA

See drug price trends for SAXENDA.

The generic ingredient in SAXENDA is liraglutide recombinant. There are seven drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the liraglutide recombinant profile page.

Generic name: liraglutide recombinant
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: February 13, 2026
Generic Entry Controlled by: United States Patent Patent 8,114,833

VICTOZA is a drug marketed by Novo Nordisk Inc. There are two patents protecting this drug and one Paragraph IV challenge.

This drug has sixty-three patent family members in twenty-seven countries. There has been litigation on patents covering VICTOZA

See drug price trends for VICTOZA.

The generic ingredient in VICTOZA is liraglutide recombinant. There are seven drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the liraglutide recombinant profile page.

Generic name: fluticasone furoate
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: March 01, 2026
Generic Entry Controlled by: United States FDA Regulatory Exclusivity

ARNUITY ELLIPTA is a drug marketed by Glaxosmithkline. There are three patents protecting this drug.

This drug has forty-six patent family members in twenty-one countries. There has been litigation on patents covering ARNUITY ELLIPTA

See drug price trends for ARNUITY ELLIPTA.

The generic ingredient in ARNUITY ELLIPTA is fluticasone furoate. There are twenty-nine drug master file entries for this API. Three suppliers are listed for this generic product. Additional details are available on the fluticasone furoate profile page.

Generic name: mechlorethamine hydrochloride
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: March 07, 2026
Generic Entry Controlled by: United States Patent Patent 7,838,564

VALCHLOR is a drug marketed by Helsinn. There are six patents protecting this drug.

This drug has fifty patent family members in twenty countries.

See drug price trends for VALCHLOR.

The generic ingredient in VALCHLOR is mechlorethamine hydrochloride. There is one drug master file entry for this API. One supplier is listed for this generic product. Additional details are available on the mechlorethamine hydrochloride profile page.

Generic name: tivozanib hydrochloride
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: March 10, 2026
Generic Entry Controlled by: United States FDA Regulatory Exclusivity

FOTIVDA is a drug marketed by Aveo Pharms. There are three patents protecting this drug.

This drug has fifty-five patent family members in twenty-six countries.

See drug price trends for FOTIVDA.

The generic ingredient in FOTIVDA is tivozanib hydrochloride. One supplier is listed for this generic product. Additional details are available on the tivozanib hydrochloride profile page.

Generic name: testosterone undecanoate
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: April 14, 2026
Generic Entry Controlled by: United States Patent Patent 11,179,402

JATENZO is a drug marketed by Tolmar. There are ten patents protecting this drug. One tentatively approved generic is ready to enter the market.

This drug has twenty-nine patent family members in fourteen countries. There has been litigation on patents covering JATENZO

See drug price trends for JATENZO.

The generic ingredient in JATENZO is testosterone undecanoate. There are sixty-nine drug master file entries for this API. Six suppliers are listed for this generic product. Additional details are available on the testosterone undecanoate profile page.

Generic name: drospirenone; estetrol
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: April 15, 2026
Generic Entry Controlled by: United States FDA Regulatory Exclusivity

NEXTSTELLIS is a drug marketed by Mayne Pharma. There are five patents protecting this drug.

This drug has two hundred and ten patent family members in forty-eight countries.

See drug price trends for NEXTSTELLIS.

The generic ingredient in NEXTSTELLIS is drospirenone; estetrol. There are eleven drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the drospirenone; estetrol profile page.

Generic name: ferric citrate
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: April 21, 2026
Generic Entry Controlled by: United States Patent Patent 8,093,423

AURYXIA is a drug marketed by Keryx Biopharms. There are three patents protecting this drug.

This drug has one hundred and twenty-two patent family members in twenty-three countries. There has been litigation on patents covering AURYXIA

See drug price trends for AURYXIA.

The generic ingredient in AURYXIA is ferric citrate. There are twenty drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the ferric citrate profile page.

Generic name: cabotegravir sodium
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: April 28, 2026
Generic Entry Controlled by: United States Patent Patent 8,410,103

VOCABRIA is a drug marketed by Viiv Hlthcare. There are two patents protecting this drug.

This drug has one hundred and twenty-six patent family members in thirty-three countries.

The generic ingredient in VOCABRIA is cabotegravir sodium. One supplier is listed for this generic product. Additional details are available on the cabotegravir sodium profile page.

Generic name: tafamidis meglumine
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: May 03, 2026
Generic Entry Controlled by: United States FDA Regulatory Exclusivity

VYNDAQEL is a drug marketed by Foldrx Pharms. There are two patents protecting this drug.

This drug has thirty-five patent family members in seventeen countries. There has been litigation on patents covering VYNDAQEL

See drug price trends for VYNDAQEL.

The generic ingredient in VYNDAQEL is tafamidis meglumine. One supplier is listed for this generic product. Additional details are available on the tafamidis meglumine profile page.

Generic name: phenylephrine hydrochloride; tropicamide
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: May 05, 2026
Generic Entry Controlled by: United States FDA Regulatory Exclusivity

MYDCOMBI is a drug marketed by Eyenovia. There are three patents protecting this drug.

This drug has forty-four patent family members in fourteen countries.

The generic ingredient in MYDCOMBI is phenylephrine hydrochloride; tropicamide. There are twenty-one drug master file entries for this API. Additional details are available on the phenylephrine hydrochloride; tropicamide profile page.

Generic name: amifampridine
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: May 06, 2026
Generic Entry Controlled by: United States FDA Regulatory Exclusivity

RUZURGI is a drug marketed by One tentatively approved generic is ready to enter the market.

This drug has forty-four patent family members in fourteen countries.

See drug price trends for RUZURGI.

The generic ingredient in RUZURGI is amifampridine. Additional details are available on the amifampridine profile page.

Generic name: dienogest; estradiol valerate
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: May 13, 2026
Generic Entry Controlled by: United States Patent Patent 8,071,577

NATAZIA is a drug marketed by Bayer Hlthcare. There are two patents protecting this drug and one Paragraph IV challenge. One tentatively approved generic is ready to enter the market.

This drug has ninety patent family members in thirty-nine countries. There has been litigation on patents covering NATAZIA

See drug price trends for NATAZIA.

The generic ingredient in NATAZIA is dienogest; estradiol valerate. There are seven drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the dienogest; estradiol valerate profile page.

Generic name: teduglutide recombinant
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: May 16, 2026
Generic Entry Controlled by: United States FDA Regulatory Exclusivity

GATTEX KIT is a drug marketed by Takeda Pharms Usa. There are two patents protecting this drug and one Paragraph IV challenge.

This drug has eight patent family members in seven countries. There has been litigation on patents covering GATTEX KIT

The generic ingredient in GATTEX KIT is teduglutide recombinant. There is one drug master file entry for this API. Two suppliers are listed for this generic product. Additional details are available on the teduglutide recombinant profile page.

Generic name: ferric carboxymaltose
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: May 31, 2026
Generic Entry Controlled by: United States FDA Regulatory Exclusivity

INJECTAFER is a drug marketed by Am Regent. There are six patents protecting this drug.

This drug has seventy-one patent family members in thirty-two countries. There has been litigation on patents covering INJECTAFER

See drug price trends for INJECTAFER.

The generic ingredient in INJECTAFER is ferric carboxymaltose. There are twenty drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the ferric carboxymaltose profile page.

Generic name: peginesatide acetate
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: June 02, 2026
Generic Entry Controlled by: United States Patent Patent 7,550,433

OMONTYS is a drug marketed by Takeda Pharms Usa. There are two patents protecting this drug.

This drug has twenty-seven patent family members in eighteen countries.

The generic ingredient in OMONTYS is peginesatide acetate. Additional details are available on the peginesatide acetate profile page.

Generic name: magnesium sulfate; polyethylene glycol 3350; potassium chloride; sodium chloride; sodium sulfate
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: June 15, 2026
Generic Entry Controlled by: United States FDA Regulatory Exclusivity

SUFLAVE is a drug marketed by Braintree Labs. There is one patent protecting this drug.

This drug has one patent family member in one country.

See drug price trends for SUFLAVE.

The generic ingredient in SUFLAVE is magnesium sulfate; polyethylene glycol 3350; potassium chloride; sodium chloride; sodium sulfate. There are one hundred and forty-six drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the magnesium sulfate; polyethylene glycol 3350; potassium chloride; sodium chloride; sodium sulfate profile page.

Generic name: histrelin acetate
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: June 16, 2026
Generic Entry Controlled by: United States Patent Patent 8,062,652

SUPPRELIN LA is a drug marketed by Endo Operations. There is one patent protecting this drug.

This drug has three patent family members in three countries.

See drug price trends for SUPPRELIN LA.

The generic ingredient in SUPPRELIN LA is histrelin acetate. There are two drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the histrelin acetate profile page.

Generic name: bupropion hydrobromide
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: June 27, 2026
Generic Entry Controlled by: United States Patent Patent 7,241,805

APLENZIN is a drug marketed by Bausch. There are eight patents protecting this drug and three Paragraph IV challenges. One tentatively approved generic is ready to enter the market.

This drug has fifty-two patent family members in eighteen countries.

See drug price trends for APLENZIN.

The generic ingredient in APLENZIN is bupropion hydrobromide. There are thirty-eight drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the bupropion hydrobromide profile page.

Generic name: perampanel
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: July 01, 2026
Generic Entry Controlled by: United States Patent Patent 8,772,497

FYCOMPA is a drug marketed by Catalyst Pharms. There are two patents protecting this drug and one Paragraph IV challenge. Three tentatively approved generics are ready to enter the market.

This drug has one hundred and one patent family members in thirty-three countries. There has been litigation on patents covering FYCOMPA

See drug price trends for FYCOMPA.

The generic ingredient in FYCOMPA is perampanel. There are five drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the perampanel profile page.

Generic name: tapentadol hydrochloride
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: July 03, 2026
Generic Entry Controlled by: United States FDA Regulatory Exclusivity

NUCYNTA is a drug marketed by Collegium Pharm Inc. There are three patents protecting this drug and four Paragraph IV challenges. Three tentatively approved generics are ready to enter the market.

This drug has forty-five patent family members in twenty-six countries. There has been litigation on patents covering NUCYNTA

See drug price trends for NUCYNTA.

The generic ingredient in NUCYNTA is tapentadol hydrochloride. There are five drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the tapentadol hydrochloride profile page.

Generic name: aliskiren hemifumarate; valsartan
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: July 03, 2026
Generic Entry Controlled by: United States Patent Patent 8,168,616

VALTURNA is a drug marketed by Novartis. There is one patent protecting this drug.

This drug has ninety-three patent family members in thirty-one countries.

The generic ingredient in VALTURNA is aliskiren hemifumarate; valsartan. There are four drug master file entries for this API. Additional details are available on the aliskiren hemifumarate; valsartan profile page.

Generic name: norgestrel
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: July 13, 2026
Generic Entry Controlled by: United States FDA Regulatory Exclusivity

OPILL is a drug marketed by Laboratoire Hra.

This drug has ninety-three patent family members in thirty-one countries.

See drug price trends for OPILL.

The generic ingredient in OPILL is norgestrel. There are twenty-five drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the norgestrel profile page.